At clinical and histological levels, VIP and nanoparticles of VIP treatment decreased the pro-inflammatory cytokine profile in the colon, reducing tight junction and ion-transporter protein expression associated with severe DSS colitis [266]. The gene discussed is VIP; the disease is colitis.